These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19332867)

  • 21. Recurrent scrotal hemangiomas during treatment with sunitinib.
    Tonini G; Intagliata S; Cagli B; Segreto F; Perrone G; Onetti Muda A; Santini D; Persichetti P
    J Clin Oncol; 2010 Dec; 28(35):e737-8. PubMed ID: 20823408
    [No Abstract]   [Full Text] [Related]  

  • 22. Extensive necrotizing fasciitis associated with sunitinib therapy.
    Piszczek J; Dalton B; Peters T; Ruether D; Urbanski S
    Clin Genitourin Cancer; 2014 Apr; 12(2):e47-9. PubMed ID: 24445249
    [No Abstract]   [Full Text] [Related]  

  • 23. How does sunitinib cause hypothyroidism?
    Hershman JM; Liwanpo L
    Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
    [No Abstract]   [Full Text] [Related]  

  • 24. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 27. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 28. Sunitinib-induced subungual splinter haemorrhage and acral erythema.
    Nakamura M; Miyachi Y
    Eur J Dermatol; 2008; 18(3):344-5. PubMed ID: 18474471
    [No Abstract]   [Full Text] [Related]  

  • 29. Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation.
    Kato T; Tomita Y; Watanabe T
    Int J Urol; 2013 Nov; 20(11):1149-50. PubMed ID: 23659419
    [No Abstract]   [Full Text] [Related]  

  • 30. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
    JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
    J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
    J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons.
    Catalá-López F
    Eur J Cancer; 2013 Mar; 49(4):984-5. PubMed ID: 23140823
    [No Abstract]   [Full Text] [Related]  

  • 34. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
    Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH
    Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
    Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
    Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
    [No Abstract]   [Full Text] [Related]  

  • 37. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
    van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
    Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
    [No Abstract]   [Full Text] [Related]  

  • 38. Sunitinib-induced acute hemolysis without hypertension: a case report.
    Jain R; Mathew P; Wood CG; Tannir NM
    Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 40. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
    Alexandrescu DT; Popoveniuc G; Farzanmehr H; Dasanu CA; Dawson N; Wartofsky L
    Thyroid; 2008 Jul; 18(7):809-12. PubMed ID: 18631016
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.